Abion Past Earnings Performance
Past criteria checks 0/6
Abion has been growing earnings at an average annual rate of 11.4%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 4.2% per year.
Key information
11.4%
Earnings growth rate
27.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -4.2% |
| Return on equity | -292.7% |
| Net Margin | -2,292.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Abion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,274 | -29,211 | 6,435 | 23,697 |
| 30 Sep 23 | 1,818 | -26,361 | 6,943 | 22,482 |
| 30 Jun 23 | 1,508 | -23,779 | 5,661 | 21,627 |
| 31 Mar 23 | 2,329 | -26,150 | 6,369 | 22,716 |
| 31 Dec 22 | 2,507 | -19,925 | 6,596 | 18,385 |
| 30 Sep 22 | 2,192 | -12,857 | 6,129 | 14,594 |
| 30 Jun 22 | 2,053 | -5,490 | 7,363 | 7,236 |
| 31 Mar 22 | 1,779 | -44,922 | 7,519 | 5,070 |
| 31 Dec 21 | 1,638 | -54,259 | 4,234 | 5,702 |
| 30 Sep 21 | 1,823 | -56,982 | 3,461 | 5,944 |
| 31 Dec 20 | 1,994 | -10,485 | 2,959 | 7,798 |
Quality Earnings: A203400 is currently unprofitable.
Growing Profit Margin: A203400 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A203400's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A203400's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A203400 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A203400 has a negative Return on Equity (-292.71%), as it is currently unprofitable.